Idorsia Ltd - Asset Resilience Ratio
Idorsia Ltd (IDIA) has an Asset Resilience Ratio of 1.63% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read IDIA total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Idorsia Ltd's Asset Resilience Ratio has changed over time. See Idorsia Ltd shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Idorsia Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Idorsia Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF0.00 | 0% |
| Short-term Investments | CHF7.39 Million | 1.63% |
| Total Liquid Assets | CHF7.39 Million | 1.63% |
Asset Resilience Insights
- Limited Liquidity: Idorsia Ltd maintains only 1.63% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Idorsia Ltd Industry Peers by Asset Resilience Ratio
Compare Idorsia Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.21% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.48% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 70.49% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for Idorsia Ltd (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Idorsia Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 3.55% | CHF17.98 Million ≈ $22.73 Million |
CHF505.89 Million ≈ $639.59 Million |
+1.00pp |
| 2023-12-31 | 2.55% | CHF12.76 Million ≈ $16.14 Million |
CHF500.00 Million ≈ $632.13 Million |
-33.98pp |
| 2022-12-31 | 36.53% | CHF330.33 Million ≈ $417.62 Million |
CHF904.18 Million ≈ $1.14 Billion |
-26.64pp |
| 2021-12-31 | 63.17% | CHF936.77 Million ≈ $1.18 Billion |
CHF1.48 Billion ≈ $1.87 Billion |
-0.87pp |
| 2020-12-31 | 64.04% | CHF919.22 Million ≈ $1.16 Billion |
CHF1.44 Billion ≈ $1.81 Billion |
-9.96pp |
| 2019-12-31 | 74.00% | CHF743.07 Million ≈ $939.44 Million |
CHF1.00 Billion ≈ $1.27 Billion |
+8.34pp |
| 2018-12-31 | 65.66% | CHF923.67 Million ≈ $1.17 Billion |
CHF1.41 Billion ≈ $1.78 Billion |
+0.58pp |
| 2017-12-31 | 65.08% | CHF840.75 Million ≈ $1.06 Billion |
CHF1.29 Billion ≈ $1.63 Billion |
-14.47pp |
| 2016-12-31 | 79.55% | CHF727.98 Million ≈ $920.36 Million |
CHF915.12 Million ≈ $1.16 Billion |
-- |
About Idorsia Ltd
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the… Read more